Neurocrine Biosciences Inc
Neurocrine Biosciences Inc price
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.
- Stock ticker
- NBIX
- Company
- Neurocrine Biosciences, Inc.
- Industry
- Healthcare
- Category
- US
- Stock split / reverse split
- --
- Launch date
- May 23, 1996
- Listed exchange
- NASDAQ
Financials
Summary: NBIX reported Revenue of 959.00M (+39.49%), beating expectations; EPS of 2.85 (+168.87%), beating expectations.
Neurocrine Biosciences Inc conversion tables
 |  |
|---|---|
| 0.5 NBIX | 356.75 BRL |
| 1 NBIX | 713.51 BRL |
| 5 NBIX | 3,567.57 BRL |
| 10 NBIX | 7,135.14 BRL |
| |
|---|---|
| 0.5 BRL | 0.00070076 NBIX |
| 1 BRL | 0.0014015 NBIX |
| 5 BRL | 0.0070076 NBIX |
| 10 BRL | 0.014015 NBIX |
More to explore
FAQ
NBIX is trading at R$713.51, -0.50% over the last 24 hours. Track live moves on the price chart at the top of this page.
The NBIX stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. NBIX is currently trading at R$713.51, -0.50% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on NBIX price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the Healthcare sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. NBIX's P/E ratio is currently 20.70 — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from NBIX; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against NBIX's historical range and other companies in the Healthcare sector.
Neurocrine Biosciences, Inc.'s market cap is currently 72.45B BRL. Market cap is calculated as stock price × total shares outstanding.
Disclaimer
The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.
OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.